Mycosis Fungoides
📧 Sign up to get email alerts when something new happens for Mycosis Fungoides.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2022-09-13Clinical Trial Update: Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies [Phase 1]
Phase 1 trial evaluating interleukin-15 in combination with avelumab in relapsed/refractory mature T-cell malignancies completed; results po…
-
CLINICAL_TRIALS trial_result · 2022-08-30Clinical Trial Update: Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma [Phase 2]
Phase 2 trial updates the combination of pembrolizumab and interferon-gamma for various mycosis fungoides/Sezary syndrome and synovial sarco…
-
FDA approval · 2022-04-27FDA Approved: BEXAROTENE — Original Application (Amneal Pharmaceuticals NY LLC)
FDA approved the original application for BEXAROTENE from Amneal Pharmaceuticals NY LLC.
-
CLINICAL_TRIALS trial_result · 2022-04-15Clinical Trial Update: FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides) [Phase 3]
A Phase 3 trial of SGX301 (synthetic hypericin) topical treatment for cutaneous T-cell lymphoma (mycosis fungoides) has completed with poste…
-
CLINICAL_TRIALS trial_result · 2022-04-08Clinical Trial Update: SOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects With Mycosis Fungoides [Phase 2]
Phase 2 trial evaluating Cobomarsen (MRG-106) versus an active comparator in Mycosis Fungoides, a form of Cutaneous T-Cell Lymphoma; study t…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2022-03-30FDA Approved: POTELIGEO — Supplemental Application (Kyowa Kirin, Inc.)
The FDA approved a supplemental application for POTELIGEO (mogamulizumab-kpkc) submitted by Kyowa Kirin, Inc.
-
CLINICAL_TRIALS trial_result · 2022-01-25Clinical Trial Update: TOtal Skin Electron Beam Therapy (Low-dose) for Tumor Clone Eradication in Early-stage Mycosis Fungoides [Phase 3]
A Phase 3 trial evaluating total skin electron beam therapy (low-dose) for eradicating tumor clones in early-stage mycosis fungoides (cutane…
-
CLINICAL_TRIALS trial_result · 2022-01-13Clinical Trial Update: Comparison of Methotrexate Versus Interferon-alfa 2b in Patients With Primary Cutaneous T-cell Lymphomas [Phase 4]
Phase 4 trial comparing methotrexate to interferon-alfa 2b in patients with primary cutaneous T-cell lymphomas (mycosis fungoides) was termi…
-
CLINICAL_TRIALS trial_result · 2021-12-14Clinical Trial Update: Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome [Phase 1]
Phase I trial evaluating recombinant human IL-15 in combination with mogamulizumab for refractory/relapsed adult T-cell leukemia/lymphoma an…
-
CLINICAL_TRIALS trial_result · 2021-11-24Clinical Trial Update: Mechlorethamine Induced Contact Dermatitis Avoidance Study [Phase 2]
Phase 2 clinical trial assessing avoidance of mechlorethamine–induced contact dermatitis in patients with cutaneous T-cell lymphoma.
-
FDA approval · 2021-03-19FDA Approved: UVADEX — Supplemental Application (Therakos LLC)
FDA approved a supplemental application for UVADEX (methoxsalen) from Therakos LLC.
-
FDA approval · 2021-01-14FDA Approved: BEXAROTENE — Original Application (Actavis Pharma, Inc.)
FDA approved Actavis Pharma, Inc.'s original application for generic Bexarotene. The drug is indicated for the treatment of cutaneous T-cell…
-
CLINICAL_TRIALS trial_result · 2020-11-16Clinical Trial Update: Lenalidomide in Treating Patients With Relapsed Mycosis Fungoides/Sezary Syndrome [Phase 2]
Phase 2 trial update of lenalidomide in relapsed mycosis fungoides/Sezary syndrome (cutaneous T-cell lymphoma) has completed; results posted…
-
FDA approval · 2020-05-01FDA Approved: VALCHLOR — Supplemental Application (Helsinn Therapeutics (U.S.), Inc.)
The FDA approved a supplemental application for Valchlor (mechlorethamine hydrochloride) filed by Helsinn Therapeutics (U.S.), Inc. This act…
-
CLINICAL_TRIALS trial_result · 2020-02-24Clinical Trial Update: Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluated Campath-1H–mediated stem cell transplant therapy for advanced Mycosis Fungoides and Sezary Syndrome; th…
-
FDA label_change · 2020-01-13FDA Approved: VALCHLOR — Supplemental Application (Helsinn Therapeutics (U.S.), Inc.)
FDA approves a supplemental application for VALCHLOR (mechlorethamine hydrochloride) to expand its labeling for the topical treatment of cut…
-
CLINICAL_TRIALS trial_result · 2019-12-05Clinical Trial Update: Clinical Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed With Mycosis Fungoides Cutaneous T-cell Lymphoma
Clinical study assessing outcomes, adverse events, treatment patterns, and quality of life in patients with Mycosis Fungoides has completed …
-
CLINICAL_TRIALS trial_result · 2019-08-29Clinical Trial Update: Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell Lymphoma [Phase 1]
A Phase 1 dose-escalation study evaluating carfilzomib with and without romidepsin in cutaneous T-cell lymphoma (CTCL) was terminated with r…
-
CLINICAL_TRIALS trial_result · 2019-05-16Clinical Trial Update: Silicon Phthalocyanine 4 and Photodynamic Therapy in Stage IA-IIA Cutaneous T-Cell Non-Hodgkin Lymphoma [Phase 1]
Phase 1 trial assessing Silicon Phthalocyanine 4 with photodynamic therapy in recurrent cutaneous T-cell lymphoma including mycosis fungoide…
-
CLINICAL_TRIALS trial_result · 2019-02-06Clinical Trial Update: Alemtuzumab in Treating Patients With Relapsed or Refractory Advanced Mycosis Fungoides or Sézary Syndrome [Phase 2]
A Phase 2 trial evaluating alemtuzumab in relapsed or refractory advanced mycosis fungoides or Sézary syndrome has completed.
-
CLINICAL_TRIALS trial_result · 2019-02-05Clinical Trial Update: Pembrolizumab in Treating Patients With Relapsed or Refractory Stage IB-IVB Mycosis Fungoides or Sezary Syndrome [Phase 2]
Phase 2 trial of pembrolizumab in relapsed or refractory mycosis fungoides or Sezary syndrome completed with results posted in 2019.
-
CLINICAL_TRIALS trial_result · 2019-01-22Clinical Trial Update: Photodynamic Therapy Using Silicon Phthalocyanine 4 in Treating Patients With Actinic Keratosis, Bowen's Disease, Skin Cancer, or Stage I or Stage II Mycosis Fungoides [Phase 1]
Phase 1 trial evaluating photodynamic therapy with silicon phthalocyanine 4 for actinic keratosis, Bowen's disease, non-melanoma skin cancer…
-
FDA approval · 2018-12-11FDA Approved: ZOLINZA — Supplemental Application (Merck Sharp & Dohme LLC)
FDA approved a supplemental application for ZOLINZA (vorinostat) from Merck Sharp & Dohme LLC.
-
CLINICAL_TRIALS trial_result · 2018-11-16Clinical Trial Update: NM-IL-12 in Cutaneous T-Cell Lymphoma (CTCL) Undergoing Total Skin Electron Beam Therapy (TSEBT) [Phase 2]
Phase 2 trial update for NM-IL-12 in Cutaneous T-Cell Lymphoma undergoing total skin electron beam therapy (TSEBT).
-
CLINICAL_TRIALS trial_result · 2018-11-14Clinical Trial Update: PUVA Maintenance Therapy in Mycosis Fungoides [Phase 3]
Phase 3 clinical trial update on PUVA maintenance therapy for patch/plaques stage Mycosis Fungoides.